Linked Life Data

19860191

Source:http://linkedlifedata.com/resource/pubmed/id/19860191

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2009-10-28
pubmed:abstractText
Combination chemotherapy with Ara-C and anthracycline anti-leukemia drugs is a standard therapeutics for acute myeloid leukemia (AML) and results in a high rate of complete remission (CR). Several salvage therapies have been established for relapse/refractory AML cases. In addition, a trial of the combination of chemotherapy with gemtuzumab ozogamicin for poor-risk AML is ongoing. The development of a new strategy including combination of conventional anti-leukemia drugs with molecule-targeting reagents might be needed to increase CR rate and cure rates by combination chemotherapy. Development of therapeutics to eradicate leukemia stem cells is also of important for increasing the cure rate of AML.
pubmed:language
jpn
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0047-1852
pubmed:author
pubmed:issnType
Print
pubmed:volume
67
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1921-5
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
[Combination chemotherapy for acute myeloid leukemia].
pubmed:affiliation
Division of Hematology, Department of Medicine, Jichi Medical University.
pubmed:publicationType
Journal Article, English Abstract, Review